Skip to content

Benjamin Panny

6 papers in the library · 77 citations · publishing 2022-2025

Papers

Sort Most recent Most cited

Lack of relationships between ketamine treatment and peripheral neurotrophic and inflammatory factors in a randomized controlled ketamine trial of major depressive disorder.

Brain, Behavior, and Immunity April 4, 2025 Manivel Rengasamy, Benjamin Panny, Zakary Hutchinson et al. 3 citations

Ketamine is a rapid-acting treatment for treatment-resistant depression (TRD), though mechanisms related to ketamine's effects remain unclear. Blood-based neurotrophic and inflammatory factors (NIFs; e.g., brain-derived neurotrophic factor, interleukin-6) have emerged as markers potentially linked to ketamine and ketamine treatment response. In this secondary analysis of a randomized controlled...

Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression.

Journal of Psychopathology and Clinical Science April 1, 2025 Shabnam Hossein, Mary L Woody, Benjamin Panny et al. 3 citations

Ketamine has shown promise in rapidly improving symptoms of depression and most notably treatment-resistant depression (TRD). However, given the heterogeneity of TRD, biobehavioral markers of treatment response are necessary for the personalized prescription of intravenous ketamine. Heterogeneity in depression can be manifested in discrete patterns of functional connectivity (FC) in default...

DOI: 10.1037/abn0000951 (opens in new tab) Full text (opens in new tab) Depression treatment Brain connectivity Mood patterns Personalized medicine +1

Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention.

Molecular Psychiatry November 1, 2024 H Nur Eken, Crystal Spotts, Benjamin Panny et al. 1 citation

In a previously published randomized controlled trial, automated self-association training (ASAT), a novel digital intervention, was found to extend the rapid antidepressant effect of a single infusion of ketamine for at least 30 days. In this secondary analysis, we aimed to understand the potential role of implicit self-esteem in the combined antidepressant effect of ketamine and ASAT...

Experiences of Awe Mediate Ketamine's Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression.

Biological Psychiatry Global Open Science July 1, 2024 Julia Aepfelbacher, Benjamin Panny, Rebecca B Price 13 citations

Ketamine, an NMDA receptor antagonist, provides rapid antidepressant effects. Although much research has focused on neural and molecular mechanisms of action, it is critical to also consider psychological mechanisms that may contribute to its therapeutic efficacy. The construct of an awe-inducing experience, which is a well-validated psychological phenomenon tied to emotional well-being, had...

DOI: 10.1016/j.bpsgos.2024.100316 (opens in new tab) Full text (opens in new tab) Mediation Mediator Psychological Ketamine therapy +4

Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression

Translational Psychiatry May 9, 2023 Jared M. Kopelman, T. Keller, Benjamin Panny et al. 57 citations

Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing neuroplasticity. In human patients, we quantified gray matter microstructural changes on a rapid (24-h) timescale within key regions where neuroplasticity enhancements post-ketamine have been implicated in animal models. In this study, 98 unipolar depressed adults who failed at least one antidepressant medication...

A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial

American Journal of Psychiatry September 21, 2022 Rebecca B Price, Crystal Spotts, Benjamin Panny et al.

Background: Intravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. We tested whether an automated, computer-based approach could efficiently leverage enhanced neuroplasticity to extend the durability of rapid clinical response. Methods: 154 adults (age 18–60) with unipolar, treatment-resistant depression were...